---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-26-027210"
form_type: "8-K"
ticker: "AIM"
cik: "0000946644"
company_name: "AIM ImmunoTech Inc."
filed_at: "2026-06-04T13:00:38+00:00"
generated_at: "2026-06-04T13:02:45.954426+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.3
calibrated_materiality_score: 0.3
confidence: "high"
source: SEC EDGAR
---

# AIM ImmunoTech highlights Ampligen preclinical data for Ebola preparedness

## Summary
- Video discusses Ampligen as prophylactic/early-onset treatment for Bundibugyo Ebola strain with no approved therapies.
- Preclinical findings: 100% protective survival with early Ampligen administration in lethal Ebola mouse model.
- Ampligen has orphan drug designation from FDA and EMA for Ebola virus disease.
- Updated Ebola-focused corporate presentation available on company website.
- CEO Thomas Equels noted urgent need for therapeutic in ongoing outbreak.

## SEC filing metadata
- accession: 0001493152-26-027210
- form_type: 8-K
- ticker: AIM
- cik: 0000946644
- company_name: AIM ImmunoTech Inc.
- filed_at: 2026-06-04T13:00:38+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.3
- calibrated_materiality_score: 0.3
- confidence: high
- sec_items: 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/946644/000149315226027210/0001493152-26-027210-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/946644/000149315226027210/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-26-027210
- JSON: https://secwatch.observer/filing/0001493152-26-027210.json
- Plain text: https://secwatch.observer/filing/0001493152-26-027210.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.